Mouse models of lipodystrophy

Key reagents for the understanding of the metabolic syndrome

Ingrid Wernstedt Asterholm, Nils Halberg, Philipp E. Scherer

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalDrug Discovery Today: Disease Models
Volume4
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Lipodystrophy
Adipose Tissue
Obesity
Leptin
Insulin Resistance
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Mouse models of lipodystrophy : Key reagents for the understanding of the metabolic syndrome. / Asterholm, Ingrid Wernstedt; Halberg, Nils; Scherer, Philipp E.

In: Drug Discovery Today: Disease Models, Vol. 4, No. 1, 2007, p. 17-24.

Research output: Contribution to journalArticle

@article{7a1fdfb7a38b4026993de2a82f7c9989,
title = "Mouse models of lipodystrophy: Key reagents for the understanding of the metabolic syndrome",
abstract = "Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.",
author = "Asterholm, {Ingrid Wernstedt} and Nils Halberg and Scherer, {Philipp E.}",
year = "2007",
doi = "10.1016/j.ddmod.2007.10.003",
language = "English (US)",
volume = "4",
pages = "17--24",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Mouse models of lipodystrophy

T2 - Key reagents for the understanding of the metabolic syndrome

AU - Asterholm, Ingrid Wernstedt

AU - Halberg, Nils

AU - Scherer, Philipp E.

PY - 2007

Y1 - 2007

N2 - Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.

AB - Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.

UR - http://www.scopus.com/inward/record.url?scp=37349063135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349063135&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2007.10.003

DO - 10.1016/j.ddmod.2007.10.003

M3 - Article

VL - 4

SP - 17

EP - 24

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 1

ER -